Israel Active

Israel’s CollPlant is partnering with US-based 3D Systems to spur breakthroughs in regenerative medicine. It brings together top 3D-printing technology with Collprint’s bioink technology for 3D bioprinting of tissues and organs.

The US FDA previously approved the brain scan software from Israel’s Aidoc ,. It has now approved all four of Aidoc’s AI products, so its comprehensive package can quickly identify and triage both ischemic and hemorrhagic stroke in CT scans.

Berlin’s caresyntax, has launched an R&D partnership with the ARC (Accelerate, Redesign, Collaborate) complex at Israel’s Sheba Medical Center. They will use Artificial Intelligence to develop algorithms for predicting responses and outcomes for cancer treatment procedures.

Tel Aviv University represented Israel on World Cancer day as one of five European cities simultaneously broadcasting news of the latest technological developments in cancer diagnosis and treatment. The event was sponsored by the NOBEL Project, which is revolutionizing healthcare in Europe.

The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX . BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity.

Israel startups Sonovia and Argaman  are racing to produce production versions of their bio-inhibitive and anti-viral textiles and masks. They could be vital prevention tools in epidemics like the deadly Wuhan coronavirus.

Israeli health company Maccabi has partnered with Israel’s Medial EarlySign .  Maccabi will integrate EarlySign’s flu algorithm, which flags people at high risk of developing flu-related complications, to target them with its vaccination campaign.

Israel’s Check-Cap has announced positive results from its latest US pilot study of its C-Scan colon capsule system. The dual-center study achieved both primary (safety) and secondary (patient satisfaction and performance) endpoints. C-Scan is already CE approved.

Following on from good Phase 2 trials Israel’s Sol-Gel reported excellent results from pivotal Phase 3 clinical trials of its Twyneo treatment of patients with acne vulgaris. The trial significantly reduced moderate-to-severe acne in 858 patients aged nine and older.

Israeli-founded Emendo Biotherapeutics, based in New York, utilizes protein engineering for precision gene editing, to treat certain genetic disorders and diseases. It has seven treatments in early stages of development. Emendo has just raised $61 million of funding.